Nicotine

# Research Output: Nicotine

**PSX ID:** PSX-0276  
**Generation Provenance ID:** ef6640ce-d920-41f7-9ffa-d4cbc4104826  
**Research Date:** 2026-04-25

---

## Chemical Identity

### Verified Data

| Field | Value | Source |
|-------|-------|--------|
| IUPAC name | 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine | PubChem CID 89594 [api_verified] |
| Systematic name | Same as IUPAC | Matches seed data exactly |
| Molecular formula | C₁₀H₁₄N₂ | PubChem CID 89594 [api_verified] |
| Molecular weight | 162.23 g/mol | PubChem CID 89594 [api_verified] |
| InChIKey | SNICXCGAKADSCV-JTQLQIEISA-N | PubChem CID 89594 [api_verified] |
| PubChem CID | 89594 | PubChem lookup [api_verified] |
| CAS number | 54-11-5 | Chemical databases [web_retrieved, Ref 39] |
| Canonical SMILES | CN1CCCC1c1cccnc1 | Chemical databases [web_retrieved, Ref 39] |
| Isomeric SMILES | CN1CCC[C@@H]1c1cccnc1 | Chemical databases [web_retrieved, Ref 39] |
| Physical state | Colorless to light yellow/brown oily liquid at room temperature | Chemical databases [web_retrieved, Ref 39] |
| Melting point | −79°C (liquid at room temperature) | Chemical databases [web_retrieved, Ref 39] |
| Boiling point | 247°C | Chemical databases [web_retrieved, Ref 39] |
| Density | 1.01 g/cm³ at 20°C | Chemical databases [web_retrieved, Ref 39] |
| Solubility | Miscible with alcohol, chloroform, ether, petroleum ether; mixes with water | Chemical databases [web_retrieved, Ref 39] |

### Stereochemistry
Nicotine is a chiral alkaloid with one asymmetric carbon at the 2′-position of the pyrrolidine ring. In nature, nicotine exists exclusively as the (S)-(−)-enantiomer (levorotatory), which constitutes >99% of alkaloid content in *Nicotiana tabacum*. The (S)-enantiomer has substantially higher binding affinity and pharmacological potency at nAChRs compared to (R)-(+)-nicotine. The naturally occurring (S)-form is the subject of all pharmacological and toxicological data reviewed here (Christen et al. 2025 [Ref 1]).

### Discrepancies with Seed Data
- **SMILES, molecular formula, molecular weight, InChIKey, PubChem CID:** All were blank in the brief — now confirmed via PubChem API and chemical databases.
- **IUPAC and systematic name:** Seed data correctly listed 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine — confirmed.

---

## Pharmacology

### Primary Receptor: Nicotinic Acetylcholine Receptors (nAChRs)

Nicotine is an agonist at neuronal nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels. Binding to the extracellular domain triggers conformational change, opening a central pore permeable to Na⁺, K⁺, and Ca²⁺. The resulting depolarization drives downstream neurotransmitter release (Wittenberg et al. 2020 [Ref 5]).

**Binding affinities at key subtypes (Stergiou et al. 2011 [Ref 7]; Xiao & Kellar 2004 [Ref 8]):**
- **α4β2 nAChR (predominant brain subtype):** [³H]nicotine Kd ≈ 19 nM; Ki (displacement of epibatidine) ≈ 20.64 nM — high-affinity binding; this is the primary molecular target underlying addiction
- **α3β4 nAChR:** Substantially lower affinity; Ki >> 1 μM for nicotine; expressed in autonomic ganglia and habenula; mediates peripheral cardiovascular effects and aversive/withdrawal signaling
- **α7 nAChR:** Very low affinity for nicotine (μM range); homopentameric; Ca²⁺-permeable; expressed in hippocampus and cortex; role in cognitive processes and as therapeutic target in Alzheimer's/schizophrenia (Lee & Hung 2022 [Ref 22])
- **α6β2* nAChR:** Key subtype in VTA dopaminergic neurons; necessary for nicotine-induced dopamine release in nucleus accumbens (Gotti et al. 2010 [Ref 32])

### Mechanism of Reward/Addiction

The mesolimbic dopamine system is the primary substrate for nicotine's rewarding and addictive effects (Kim & Picciotto 2023 [Ref 6]; Wittenberg et al. 2020 [Ref 5]; Balfour 2009 [Ref 30]):

1. **Nicotine binds α4β2* and α6β2* nAChRs** on dopaminergic neurons in the ventral tegmental area (VTA)
2. **Direct activation** of VTA dopamine neurons → phasic burst firing
3. **Increased dopamine release** in nucleus accumbens shell (primary reward signal)
4. **Indirect disinhibition:** Chronic nicotine upregulates α4* nAChRs on VTA GABAergic interneurons → increased GABAergic tone → reduced dopamine neuron baseline firing (tolerance mechanism) (Ngolab et al. 2015 [Ref 26, from PMID 26041923])
5. **Walker et al. 2023:** β2* nAChR activation on VTA neurons is sufficient for nicotine reinforcement in rats (PMID 37193602)

**Non-dopaminergic pathways** (Kim & Picciotto 2023 [Ref 6]):
- **Glutamate/GABA in mesolimbic system:** Novel signaling mechanisms supplementing dopaminergic reward
- **Habenula-interpeduncular (Hb-IP) pathway:** Chronic nicotine sensitizes MHb nAChRs; antagonism of Hb-IP nAChRs triggers withdrawal; this circuit drives nicotine aversion and withdrawal (Arvin et al. 2019 [Ref 33])
- **HPA axis effects:** Nicotine self-administration augments adrenocorticotropic hormone and corticosterone responses to stress

### Catecholamine/Neurotransmitter Release
Beyond central dopamine, nicotine stimulates:
- **Norepinephrine release:** Via α3β4 nAChRs on peripheral postganglionic sympathetic nerve endings and adrenal medulla → tachycardia, increased BP, vasoconstriction (Haass & Kübler 1997 [Ref 20])
- **Dopamine, norepinephrine, and serotonin** released across hippocampus, prefrontal cortex, VTA, and nucleus accumbens (Singer et al. 2004 [Ref from PMID 15453274])
- **Acetylcholine:** Indirect modulation of cholinergic transmission

### Pharmacological Class Clarifications
- **Nicotinic acetylcholine receptor agonist:** Primary mechanism
- **Dopamine releasing agent:** Indirect, via nAChR-mediated VTA activation
- **Norepinephrine releasing agent:** Via peripheral sympathetic nAChR stimulation
- **β-carboline MAO inhibitors in tobacco smoke** (harman, norharman): Inhibit MAO-A and MAO-B, potentiating dopamine availability; contribute ~10% or less of total MAO-A inhibitory activity from cigarette smoke but affect DAT activity (Hong et al. 2022 [Ref 18]; Saro et al. 2025 [Ref 19]). **Note:** These are tobacco combustion products, NOT nicotine itself. Pure nicotine does not have direct MAO inhibitory activity.

### Pharmacokinetics (Human Data)

Primary source: Hukkanen, Jacob & Benowitz (2005) [Ref 3] — the definitive pharmacokinetic review; supplemented by Benowitz, Hukkanen & Jacob (2009) [Ref 4].

**Absorption:**
| Route | Bioavailability | Tmax | Notes |
|-------|----------------|------|-------|
| Smoked/inhaled | ~30% (range 20–50%) | 5–10 min | Variable based on puff volume, depth; rapid arterial spike |
| Oral | ~20–45% | 60–90 min | Significant first-pass hepatic metabolism; food delays absorption |
| Buccal/sublingual | ~70–90% | 15–30 min | Avoids first-pass; pH-dependent (ionized at acidic pH) |
| Transdermal | ~70–100% | 6–10 hours | Slow, sustained delivery |

- Nicotine is a weak base (pKa ~8.0); absorption is pH-dependent; less ionized at alkaline pH → faster buccal/nasal absorption
- Smoked nicotine reaches the brain within 10–20 seconds of inhalation — fastest delivery of any common route

**Distribution:**
- Volume of distribution: ~2.6 L/kg (extensive tissue binding)
- Protein binding: <5% (very low)
- Crosses blood-brain barrier readily (lipophilic, low molecular weight, low protein binding)
- Crosses placenta; concentrates in fetal tissues; present in breast milk

**Metabolism — CYP2A6 as primary enzyme (Hukkanen et al. 2005 [Ref 3]):**
- **~70–80% of nicotine** metabolized to **cotinine** via CYP2A6 (liver) — cotinine has low pharmacological activity
- Cotinine → trans-3′-hydroxycotinine (3HC) via CYP2A6 (major urinary metabolite)
- **3HC:cotinine ratio** = validated biomarker of CYP2A6 activity; predicts nicotine clearance rate (Levi et al. 2007 [Ref 13])
- Minor pathways: FMO3 → nicotine-1′-N-oxide; UGT → glucuronides; N-methyltransferase → nornicotine pathway
- **CYP2A6 genetic variants** significantly alter metabolism: poor metabolizers clear nicotine slowly → tend to smoke fewer cigarettes; ultrarapid metabolizers smoke more (Benowitz et al. 2006 [Ref 14])

**Factors affecting CYP2A6 activity (Benowitz et al. 2009 [Ref 4]):**
- Oral contraceptives/estrogen: induce CYP2A6 → faster nicotine clearance in women
- Pregnancy: increases CYP2A6 activity → accelerated clearance
- Grapefruit juice: inhibits CYP2A6 → increased nicotine plasma levels
- Methoxsalen (8-MOP): potent CYP2A6 inhibitor; doubles nicotine plasma half-life
- Racial/ethnic differences: Asian populations have higher frequency of reduced-function CYP2A6 alleles

**Elimination:**
- Plasma half-life of nicotine: **~2 hours** (range 1–4 hours depending on metabolizer status)
- Cotinine half-life: **~16–19 hours** (used as biomarker with 4–7 day detection window)
- Primarily renal excretion as metabolites; <5% excreted unchanged
- Cotinine in blood: preferred biomarker for nicotine exposure; cut-point ≥3 ng/mL distinguishes smokers from non-smokers (Benowitz et al. 2009 [Ref 4])

---

## History

**Pre-isolation era:**
- Tobacco (*Nicotiana tabacum* and *N. rustica*) used by indigenous peoples of the Americas for centuries before European contact
- 1492: Columbus and crew first observed tobacco use in the Caribbean
- Named after Jean Nicot de Villemain, French ambassador to Portugal, who promoted tobacco use as medicine in the 1560s
- The genus *Nicotiana* was named for Nicot by Carl Linnaeus

**Discovery and characterization (web_retrieved [Ref 26]):**
- **1828:** Nicotine isolated from tobacco leaves by German chemists **Wilhelm Heinrich Posselt** (physician, 1806–1877) and **Karl Ludwig Reimann** (chemist, 1804–1872). They recognized it as a poison.
- **1843:** Empirical molecular formula described by Melsens
- **1893:** Chemical structure determined by Adolf Pinner and Richard Wolffenstein
- **1904:** First total synthesis by Amé Pictet and A. Rotschy
- Nicotine constitutes >90% of tobacco alkaloid content (2–8% of dry leaf mass)

**Modern pharmacology history:**
- 1940s–1950s: Role of nicotinic receptors in autonomic ganglia and neuromuscular junction characterized
- 1988: US Surgeon General's Report formally declared nicotine an addictive substance comparable to heroin and cocaine
- 1990s: Development of nicotine replacement therapies (patches, gum); varenicline approved 2006
- 2000s–present: E-cigarette proliferation creates new pharmacokinetic delivery profiles; regulatory expansion

---

## Subjective Effects

**From controlled human and animal studies:**

### Stimulant/Arousal Effects
Nicotine produces dose-dependent stimulatory effects: increased alertness, improved attention, reduced reaction time, and enhanced concentration at low-to-moderate doses (Valentine & Sofuoglu 2018 [Ref 23]). These effects are particularly pronounced in nicotine-naive individuals and may be somewhat confounded by withdrawal relief in dependent users.

### Cognitive Effects
- **Attention/vigilance:** Consistently enhanced in controlled studies, particularly for sustained attention tasks (Valentine & Sofuoglu 2018 [Ref 23])
- **Working memory:** Animal data robustly supports enhancement; human data more mixed (Grus & Hromatko 2019 [PMID 32623864] found no acute cognitive enhancement in young occasional smokers in at least one controlled study)
- **Mood elevation:** Mild positive affect, relaxation, reduced anxiety despite stimulant class
- **Late-life depression and cognition:** Nicotine may have therapeutic potential for improving mood and cognition in late-life depression populations via nAChR network effects (Gandelman et al. 2018 [PMID 28859996])
- Adolescent brain differences: heightened reward response, less withdrawal aversion vs. adults (Colyer-Patel et al. 2023 [Ref 31])

### Physical Effects
- **Cardiovascular:** Heart rate increase, elevated blood pressure, vasoconstriction, increased myocardial oxygen demand (Haass & Kübler 1997 [Ref 20]; Chagué et al. 2015 [Ref 28])
- **Gastrointestinal:** Nausea and vomiting at higher doses (particularly naive users); appetite suppression
- **Pupil response:** Mild miosis (constriction) at low doses consistent with seed data taxonomy
- **Salivation:** Increased glandular secretion
- **Sweating:** Autonomic activation causes perspiration

### Route-Specific Subjective Features
- **Smoked:** Rapid "hit" within seconds; intense brief peak; satisfaction largely from speed of delivery
- **Oral/buccal:** Slower onset; more sustained; less intense peak
- **Nasal/spray:** Intermediate onset

---

## Safety & Toxicity

### Acute Toxicity / LD50 Re-Evaluation
**Critical note — seed data is CORRECT on this point:**

The historically cited oral LD50 of 30–60 mg for humans has been **thoroughly refuted** by Mayer (2014) [Ref 17], who traced this figure back to dubious 19th-century self-experiments by Kobert that were uncritically repeated through circular citation. Mayer's systematic re-evaluation of published human poisoning data established that:
- **Lower limit for fatal nicotine ingestion ≈ 0.5–1.0 g**
- **Estimated oral LD50 in humans ≈ 6.5–13 mg/kg body weight**

This matches the seed data ("estimated oral LD50 of 6.5–13 mg/kg in humans") and is the currently accepted figure. **The seed data is CONFIRMED.**

**Implication:** A 70 kg adult would require approximately 455–910 mg of ingested nicotine for a 50% lethal dose — substantially more than one cigarette's content (~10–15 mg) but potentially achievable with concentrated liquid nicotine solutions (e-cigarette refill liquids can contain 18–24 mg/mL or higher).

### Nicotine Poisoning — Acute Clinical Presentation
**Green Tobacco Sickness (GTS):** Occupational illness caused by transdermal nicotine absorption during wet tobacco harvesting. Symptoms: nausea, vomiting, headache, abdominal cramps, dizziness, excessive sweating (Jahromi et al. 2026 [Ref 10]; McMahon 2019 [Ref 11]):
- Global prevalence: 23.6% of tobacco farmworkers (17,609 workers, 17 studies)
- Women have higher prevalence (37.3%) than men (21.7%)
- 8 million individuals affected annually worldwide
- Higher temperatures/climate change projected to worsen prevalence (Ziska & Parks 2024 [Ref 25])

**E-cigarette/liquid nicotine poisoning (Ahmed 2022 [Ref 12]):** Rising reports to US poison control centers since 2007 introduction of e-cigarettes; children particularly at risk from accidental ingestion; liquid nicotine concentration greatly exceeds cigarette content

**Symptom progression in acute nicotine intoxication:**
- *Mild:* Nausea, vomiting, salivation, headache, pallor, diaphoresis
- *Moderate:* Tachycardia → bradycardia, hypotension, tremor, ataxia
- *Severe/Lethal:* Seizures, respiratory failure, cardiac arrhythmia, death

### Cardiovascular Risks
- Increases heart rate, blood pressure, and myocardial oxygen consumption simultaneously
- Decreases coronary blood flow via vasoconstriction → particularly dangerous in coronary artery disease
- Paradoxical coronary vasoconstriction can occur during exercise
- Platelet activation and pro-thrombotic effects (Chagué et al. 2015 [Ref 28]; Benowitz & Liakoni 2022 [Ref 41])
- Arrhythmia risk in vulnerable individuals (Chagué et al. 2015 [Ref 28])

### Teratogenicity / Developmental Toxicity
- Crosses placenta readily; accumulates in amniotic fluid and fetal tissues
- nAChRs expressed early in gestation; nicotine interferes with normal neurotrophic signaling (Beltrán-Castillo et al. 2023 [Ref 16])
- **Sudden Infant Death Syndrome (SIDS):** Prenatal nicotine linked to altered respiratory neural network development
- Fetal effects: impaired lung development, low birth weight, cerebral cortex and hippocampal alterations
- Cleft palate: nicotine exposure during pregnancy associated with persistent midline epithelial seam (PMID 26443016)
- England et al. (2015) [Ref 37]: NRT is NOT demonstrably safe in pregnancy — nicotine itself (not just combustion) causes developmental harm

---

## Harm Reduction

### Contraindications (from published literature)
- **Pregnancy:** Absolute contraindication for non-therapeutic nicotine use; teratogenic, SIDS risk (Beltrán-Castillo et al. 2023 [Ref 16]; England et al. 2015 [Ref 37])
- **Cardiovascular disease:** Coronary artery disease, recent myocardial infarction, severe uncontrolled hypertension, serious cardiac arrhythmias — relative contraindication
- **Active peptic ulcer disease:** Nicotine stimulates gastric acid secretion
- **Pheochromocytoma:** Risk of hypertensive crisis

### Safer Use Guidance
- **Dose delivery method matters:** NRT (patches, gum, lozenges) delivers substantially safer pharmacokinetic profiles vs. smoked cigarettes due to slower absorption, absence of combustion toxicants
- Cochrane evidence (Stead et al. 2012 [Ref 9]; Theodoulou et al. 2023 [Ref 35]): all NRT formulations increase quit rates 50–70% over placebo; harm reduction utility is well-established
- Bupropion and varenicline augment NRT efficacy for cessation
- Avoid using liquid nicotine concentrates (e-cigarette refills) without proper safety handling — risk of accidental poisoning

### Testing
No standard field test exists for nicotine; it is a known compound. For cessation verification: urine/blood cotinine measurement (threshold ≥3 ng/mL plasma = smoker) (Benowitz et al. 2009 [Ref 4]).

---

## Tolerance & Dependence

### Tolerance Development
Nicotine tolerance develops **rapidly — within hours to days of repeated exposure**:
1. **Acute tachyphylaxis:** Desensitization of nAChRs within minutes of sustained nicotine exposure (receptor switches from active → desensitized state)
2. **Chronic upregulation:** Paradoxically, chronic nicotine exposure upregulates α4β2* nAChR density by 20–100% in most brain regions, particularly in high-affinity binding sites (Nguyen, Rasmussen & Perry 2003 [Ref 44]; Whiteaker et al. 1998 [Ref 43])
3. **GABAergic mechanism:** In VTA, α4* upregulation on GABAergic neurons increases inhibitory tone on dopamine neurons → blunted dopamine response = tolerance (Nashmi et al. 2007 [PMID 17670967])
4. **Hb-IP sensitization:** Habenulo-interpeduncular circuit sensitization during chronic exposure creates withdrawal vulnerability (Arvin et al. 2019 [Ref 33])
5. **Receptor normalization during abstinence:** β2* nAChRs remain elevated at 7 days abstinence in human smokers vs. non-smokers — upregulation lasts days to weeks (Staley et al. 2006 [Ref 45 — note: PMID correction needed; paper is PMID 16928859])

**Cross-tolerance:** To other nicotinic agonists (e.g., cytisine, varenicline effects); also influences opioid system (adolescent nicotine exposure increases future opioid vulnerability, PMID 31445026)

### Dependence
- **Extremely high addiction potential** — one of the most addictive psychoactive substances; the seed data designation "extremely addictive with high potential for abuse" is fully supported
- DSM-5 Tobacco Use Disorder (TUD) criteria: tolerance, withdrawal, use in larger amounts, inability to cut down, significant time spent using, craving, continued use despite problems
- GWAS of nicotine dependence: strong genetic correlations with other SUDs, psychiatric disorders, lung cancer; CHRNA5 locus (α5 nAChR subunit) is most replicated locus (Johnson et al. 2025 [PMID 40831304])
- Social/behavioral reinforcement contributes alongside pharmacological factors; women more influenced by non-nicotine smoking cues (Perkins et al. 1999 [PMID 11072427])

### Withdrawal Syndrome
DSM-IV-TR/DSM-5 criteria (Miyasato 2013 [Ref 34]): onset typically within **4–24 hours** of last dose; peak at 24–72 hours; most symptoms resolve within 2–4 weeks:
1. Dysphoric or depressed mood
2. Insomnia
3. Irritability, frustration, or anger
4. Anxiety
5. Difficulty concentrating
6. Restlessness
7. **Decreased heart rate** (reversal of nicotine-induced tachycardia)
8. Increased appetite or weight gain

**Physical withdrawal symptoms** (distinct from psychological) driven by α2, α3, α5, β4 subunits in habenular complex and target regions (Wittenberg et al. 2020 [Ref 5]).

---

## Interactions

### Cannabis (Brief flagged: "caution")
**Published evidence (Filbey et al. 2018 [Ref 38]; de la Salle et al. 2019 [Ref 21]):**
- Combined cannabis and nicotine use produces **distinct brain network effects** not seen with either substance alone
- Resting-state network: combined users show different functional connectivity patterns vs. isolated cannabis or nicotine users; combined users had connectivity closer to non-users in some networks — complex and non-additive interaction
- Auditory deviance detection: nabilone (CB1 agonist) + nicotine combined showed frontal MMN enhancement vs. impairment from either alone
- Combined hippocampal effects: MJ+NIC users show smaller hippocampal volumes with inverted brain-behavior memory relationships (Filbey et al. 2015 [PMID 26187691])
- **Clinical implication:** The "caution" flag in the seed data is supported — combined use produces poorly predictable synergistic effects, increased risk of tobacco dependence development when cannabis is smoked with tobacco

### MAOIs (tobacco smoke component interaction)
- Tobacco smoke contains multiple MAO inhibitors: beta-carbolines (harman, norharman), hydroquinones, polyunsaturated fatty acids (Hong et al. 2022 [Ref 18]; Saro et al. 2025 [Ref 19])
- These MAOIs **potentiate dopaminergic effects** of nicotine by reducing dopamine degradation and stimulating DAT-mediated dopamine release
- **Pure nicotine + clinical MAOIs:** Rached et al. (2026) [Ref 42] — in their 219-publication review, nicotine can be used with careful monitoring in MAOI patients; does not appear to carry serotonin syndrome risk; primarily monitored for cardiovascular effects (BP/HR augmentation)
- **FLAG for review:** The specific pharmacodynamic interaction between pure nicotine and pharmaceutical MAOIs in humans is understudied; evidence is primarily indirect from tobacco smoke studies

### Oral Contraceptives / Estrogen
- Oral contraceptives and estrogen-containing hormone preparations induce CYP2A6 → accelerated nicotine metabolism → women on OCs may require higher doses or experience faster dependence cycling (Hukkanen et al. 2005 [Ref 3])

### CYP2A6 Inhibitors (pharmacokinetic)
- Methoxsalen, tranylcypromine, oral artemisinin: inhibit CYP2A6 → increased nicotine plasma levels (~2× half-life extension with methoxsalen) (Damaj et al. 2007 [PMID 17021260])
- Grapefruit juice: CYP3A4/CYP2A6 inhibition → modest increases in nicotine plasma levels (Hukkanen et al. 2006 [PMID 17112808])

### Cardiovascular Drug Interactions
- **Beta-blockers:** Nicotine's sympathomimetic effects may partially overcome beta-blockade
- **Antihypertensives:** Nicotine consistently raises blood pressure; reduces antihypertensive efficacy
- **Adenosine:** Nicotine may reduce efficacy of adenosine-based therapies

### Physiological Interactions
- **Bupropion:** Combination with NRT is synergistic for cessation; bupropion acts on norepinephrine/dopamine transport with nAChR antagonist activity
- **Varenicline:** α4β2 partial agonist; when combined with NRT may cause nausea/side effects (see NCT01574703)

---

## Legal Status

### United States
- Nicotine is **not** a controlled substance under the Controlled Substances Act (DEA)
- Regulated as a **tobacco product** under the Family Smoking Prevention and Tobacco Control Act (2009) — FDA regulatory authority over cigarettes, smokeless tobacco, e-cigarettes, and all nicotine-containing products
- **April 14, 2022:** Synthetic nicotine brought under FDA jurisdiction via Consolidated Appropriations Act 2022
- **January 2025:** FDA issued proposed rule to limit nicotine levels in combusted cigarettes to minimally addictive or non-addictive levels (Federal Register, Jan. 16, 2025) [Ref 27]
- NRT products (patches, gum, lozenges, inhalers) regulated as **over-the-counter drugs** by FDA

### United Kingdom
- Nicotine is **not** a controlled substance under the Misuse of Drugs Act
- Nicotine pouches regulated as general consumer products under General Product Safety Regulations (limited oversight)
- NRT products regulated as medicines by MHRA

### European Union
- Nicotine not scheduled at EU level
- Tobacco Products Directive (TPD, 2014) governs cigarettes and vaping products
- **TPD3** revision in development; expected to introduce uniform EU-wide nicotine pouch regulation (~2027)
- Member state approach varies: France, Germany, Belgium, Netherlands have banned oral nicotine pouches; Sweden permits

### Australia
- Nicotine vaping products require a **prescription** since October 1, 2021 (Therapeutic Goods Administration)
- Nicotine pouches commercially illegal without prescription
- Cigarettes and smoking tobacco regulated under tobacco laws

### Canada
- Nicotine pouches restricted to **pharmacy-only sales** since 2024 (behind the counter)
- Cigarettes, vaping products regulated under the Tobacco and Vaping Products Act

---

## Clinical Trials

### NCT00873392 — Transdermal Nicotine in Parkinson's Disease
- **Status:** COMPLETED
- **Phase:** Phase 2
- **Sponsor:** Assistance Publique – Hôpitaux de Paris
- **Condition:** Idiopathic Parkinson's Disease
- **Intervention:** Transdermal nicotine patch for motor symptoms
- **Relevance:** Explores neuroprotective/therapeutic potential of nicotine via α7 and other nAChRs; rationale from epidemiological inverse correlation between smoking and PD incidence

### NCT01574703 — EAGLE Study: Cardiac Safety of Cessation Medications
- **Status:** COMPLETED
- **Phase:** Phase 4
- **Sponsor:** Pfizer
- **Condition:** Smoking cessation
- **Interventions:** Varenicline, bupropion, NRT (nicotine patch), placebo
- **Relevance:** Definitive cardiac safety data for nicotine replacement therapy; large Phase 4 trial

### NCT00916721 — Memory Reconsolidation Blockade for Nicotine Dependence
- **Status:** COMPLETED
- **Phase:** Phase 3
- **Sponsor:** Massachusetts General Hospital
- **Condition:** Smoking cessation (nicotine dependence)
- **Relevance:** Psychological/pharmacological approach to disrupting cue-induced nicotine craving via memory reconsolidation

### Emerging Research Directions (from recent literature)
- GLP-1 receptor agonists (semaglutide, liraglutide) reduce nicotine self-administration; clinical trials ongoing for smoking cessation (Falk et al. 2023 [PMID 37148870])
- Oxytocin as adjunct for nicotine withdrawal; preliminary clinical trial evidence (Thanekar et al. 2026 [PMID 41687409])
- Very Low Nicotine Content (VLNC) cigarettes as regulatory/harm reduction strategy (Tidey et al. 2022 [PMID 35642796])

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. This section is not applicable.

---

## Gaps & Flags

### ⚠️ Safety-Critical Items

**1. SMILES String — Not API-Verified**
- PubChem API returned molecular formula, weight, and InChIKey but NOT SMILES (page requires JavaScript rendering)
- SMILES confirmed from chemical databases [Ref 39] as CN1CCC[C@@H]1c1cccnc1 (isomeric S-form) and CN1CCCC1c1cccnc1 (canonical)
- **STATUS:** web_retrieved only; generation agent should treat with appropriate caution; generation agent should confirm via additional PubChem database lookup if possible

**2. Oral LD50 (Seed Data CONFIRMED, Historical Figure INCORRECT)**
- Seed data states "estimated oral LD50 of 6.5–13 mg/kg in humans" — **CONFIRMED** by Mayer (2014) [Ref 17] peer-reviewed re-evaluation
- The commonly cited 30–60 mg absolute dose (frequently appearing elsewhere online) is **INCORRECT** per Mayer 2014 and should not be used
- This is a critical safety flag: the 30–60 mg figure led to overestimation of nicotine lethality risk; the Mayer re-evaluation substantially raises the estimated lethal dose but liquid nicotine concentrations in e-cigarette refills (up to 100+ mg/mL) can still represent meaningful acute poisoning risk

**3. Cannabis Interaction — "Caution" Justified But Poorly Characterized**
- The seed data flags cannabis interaction at "caution" severity — supported by published evidence showing complex, non-linear interactions
- Specific pharmacodynamic mechanism (CB1/nAChR crosstalk) not fully characterized in humans
- **FLAG:** Generation agent should note this is an interaction with published evidence but mechanism is incompletely understood; caution severity is appropriate

### Missing Data Points

**4. Specific Ki/EC50 at Dopamine and Norepinephrine Transporters**
- Nicotine does not act directly on monoamine transporters; its catecholamine-releasing effects are indirect (via nAChR activation). No direct DAT/NET binding data for nicotine — this is appropriate (no gap in understanding, just clarification needed)

**5. Tolerance Buildup Timeline — Partially Confirmed**
- Seed data: tolerance builds "rapidly with prolonged and repeated use" — confirmed by multiple published sources
- Seed data: half-life for tolerance 5 days; full reset 1.5 weeks — these are reasonable estimates consistent with clinical NRT literature and receptor normalization studies (Staley et al. 2006) but specific studies confirming exact 5-day half-life or 1.5-week reset period were not located in the searched literature. **FLAG for editorial review.**

**6. Specific Dose-Response Data in Controlled Human Studies**
- Published controlled dosing studies are largely from NRT literature and use product-normalized doses rather than pure nicotine mg doses
- The dose thresholds in the seed data (e.g., smoked threshold 0.2 mg, heavy 3.5+ mg) are consistent with published NRT and cigarette delivery literature but were not validated against a single primary study
- **FLAG:** These are reasonable evidence-based estimates; editorial review of dose data is appropriate before publication

**7. Interaction with Specific Cardiovascular Medications**
- Detailed data on interactions with antiarrhythmics, calcium channel blockers, and other cardiovascular drugs is limited in the searched literature
- The general principle (additive sympathomimetic effects) is well-established but specific interaction studies are sparse

**8. Legal Status — Australia NRT Products**
- NRT products (patches, gum) in Australia appear to be OTC but specific regulation not confirmed in searched sources

**9. Physical Property — pKa and LogP**
- pKa ~8.0 (pyrrolidine nitrogen) and LogP ~1.17 are commonly cited values; not confirmed from api_verified source in this research run. These values are important for predicting absorption pH-dependence (buccal absorption)

### Data Confirmed as Correct in Seed Brief

- Systematic/IUPAC name: ✅ Confirmed
- Chemical class (pyrrolidine, pyridine, substituted pyrrolidine): ✅ Confirmed
- Pharmacological class: ✅ Confirmed (nAChR agonist, DA releasing agent, NE releasing agent)
- Primary ROA (buccal) and known ROAs: ✅ Clinically consistent
- Oral LD50 estimate 6.5–13 mg/kg: ✅ Confirmed (Mayer 2014)
- Psychoactive class (stimulant): ✅ Confirmed
- Characterization (established): ✅ Confirmed — one of the world's most studied psychoactive compounds